ALSO READDr Reddys Laboratories announces successful USFDA inspection of its API Srikakulam Plant Dr Reddys Laboratories to pay dividend for FY 2017 Dr Reddys Laboratories launches Ezetimibe and Simvastatin Tablets Dr Reddys Laboratories launches Bivalirudin for Injection Dr Reddys Laboratories intimates of successful inspection of its formulations Srikakulum Plant Unit II
Receives one observation in Form 483Dr Reddys Laboratories announced that the audit of its Formulations Srikakulam Plant (SEZ) Unit I, Andhra Pradesh, by the US FDA, has been completed on 16 June 2017. The Company has been issued a Form 483 with one observation.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)